Rapid diagnostics Guanine’s electrochemical platform aims to deliver rapid, culture-free sepsis profiling and pathogen identification within minutes, presenting a clear value proposition for hospitals seeking faster clinical decision support and improved antimicrobial stewardship.

OEM collaboration The company is pursuing OEM partnerships to accelerate assay development, reduce system cost and complexity, and expand multiplexing across infectious diseases and chronic conditions, creating unique cross-sell opportunities for diagnostic device manufacturers and AI-driven health applications.

Multi-omic potential A high-plex, multi-omic electrochemical layer enables simultaneous measurement of proteins, metabolites, nucleic acids, and drug response, offering a broad platform upside for expanding diagnostic panels and enabling next-generation precision health solutions.

Clinical partnerships Active collaboration with Mount Sinai Health Systems and ongoing engagement with clinical partners indicate strong routes to validation, real-world data, and pilot programs that can be leveraged for customer pilots and evidence-based sales pitches.

Early-stage monetization With current revenue under one million and a strategic focus on sepsis workflows, there is an opportunity to target early adopters in hospital networks and regional labs with scalable, cost-effective solutions that address urgent time-to-result needs.